Neurologic Status of Patients with Purine Nucleoside Phosphorylase Deficiency Before and After Hematopoetic Stem Cell Transplantation
Authors:
- 20 September 2023
- journal article
- research article
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 43 (8) , 2062-2075
Abstract
Background Purine nucleoside phosphorylase (PNP) deficiency is a rare autosomal recessive combined immunodeficiency. The phenotype is profound T cell deficiency with variable B and NK cell functions and results in recurrent and persistent infections that typically begin in the first year of life. Neurologic findings occur in approximately two-thirds of patients. The mechanism of neurologic abnormalities is unclear. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for PNP deficiency. Methods We report here six patients from five unrelated families with PNP deficiency treated in two centers in Turkey. We evaluated the neurological status of patients and compared to post-transplantation period if available. Then, we performed PubMed, Google Scholar, and Researchgate searches using the terms “PNP” and “hematopoietic stem cell transplantation” to find all reported cases of PNP transplantation and compared to our cohort. Results Six patients were treated in two centers in Turkey. One patient died from post-transplant complications. The other four patients underwent successful HSCT with good immune reconstitution after transplantation (follow-up 21–48 months) and good neurological outcomes. The other patient with a new mutation is still waiting for a matching HLA donor. Discussion In PNP deficiency, clinical manifestations are variable, and this disease should be considered in the presence of many different clinical findings. Despite the comorbidities that occurred before transplantation, HSCT currently appears to be the only treatment option for this disease. HSCT not only cures immunologic disorders, but probably also improves or at least stabilizes the neurologic status of patients.Keywords
All Related Versions
Funding Information
- Research Fund of Istanbul University-Cerrahpasa (TOA-2021-35251)
This publication has 32 references indexed in Scilit:
- Cross Correction Following Haemopoietic Stem Cell Transplant for Purine Nucleoside Phosphorylase Deficiency: Engrafted Donor-Derived White Blood Cells Provide Enzyme to Residual Enzyme-Deficient Recipient Cells2012
- Effects of purine nucleoside phosphorylase deficiency on thymocyte developmentJournal of Allergy and Clinical Immunology, 2011
- Purine nucleoside phosphorylase deficiency in two unrelated Saudi patientsAnnals of Saudi Medicine, 2009
- An unconditioned bone marrow transplantation in a child with purine nucleoside phosphorylase deficiency and its unique complicationPediatric Transplantation, 2008
- Successful HLA‐identical hematopoietic stem cell transplantation in a patient with purine nucleoside phosphorylase deficiencyPediatric Transplantation, 2007
- Purine Nucleoside Phosphorylase Deficiency in a Patient With Spastic Paraplegia and Recurrent InfectionsJournal of Child Neurology, 2007
- Unrelated cord blood transplantation for second hemopoietic stem cell transplantationPediatrics International, 2003
- Two novel missense and frameshift mutations in exons 5 and 6 of the purine nucleoside phosphorylase (PNP) gene in a severe combined immunodeficiency (SCID) patientHuman Genetics, 1996
- Correction of purine nucleoside phosphorylase deficiency by transplantation of allogeneic bone marrow from a siblingThe Journal of Pediatrics, 1996
- Lymphocyte dysfunction caused by deficiencies in purine metabolismImmunology Today, 1981